main menu

Pages

A waiting vaccine against Corona in September



London has revealed that a coronavirus vaccine may be ready by next September, and Sarah University's Professor Sarah Gilbert, who is currently leading Britain's most advanced research on a vaccine, said she is “80 per cent confident” that her team's development will work by fall.

Gilbert said she had hoped the vaccine would be developed by the end of 2020, but has now confirmed the most optimistic scenario after human trials begin in the next two weeks.

And British reports, at the end of last March and reported by Elaf, said that human and animal experiments on a British vaccine against Corona virus will begin within weeks at the government secret science base (Burton Down) in Wiltshire County.

Scientists will test the drug, made at Oxford University, on animals at the base before it tests on humans this week. Oxford scientists hope that the vaccine - which contains a section of the genetic code from the coronavirus - will train the body to attack the virus.

Animal experiments

The newspaper (The Times) said that the trials of the second stage will start before the results of animal experiments are known, as the crisis moves to its next dramatic stage, however, experts warned that the Covid-19 vaccine is not imminent.

The British government had announced earlier that it would finance the manufacture of millions of vaccine doses that seemed promising in advance, allowing immediate availability to the public once it was developed.

In addition, despite previous warnings that vaccine production could take up to 18 months, Professor Gilbert said the most bullish scenario for a working product is September "if everything goes perfectly".

She told the Times: "I think there is a great opportunity to work on the basis of other things we've done with this type of vaccine." She added: "It's not just intuition, and with each passing week we have more data to look at. I'm going to get 80 percent of Results, this is my personal point of view. "

Shutdown and test

The vaccine scientist Gilbert explained that the closure of Britain makes it difficult to test a vaccine because of the inability of the virus to spread, and said: 'No one can promise that it will work.'
Professor Gilbert's team was already in talks with the government on production to avoid any delays, and to avoid a second high infection in the fall. "We don't want to reach later this year and find that we have a highly effective vaccine and we don't have any vaccine to use," she said.
British ministers had hinted that it might be beneficial to spend tens of millions on an effective vaccine to offset the economic cost of the closure. The UK is a leader in vaccine financing, and pumped 210 million pounds into an international fund last month - the largest contribution at the time to the vaccine.

Millions of doses

The government also said it would be willing to purchase millions of doses if the trials proved successful. However, despite the optimism from Oxford, other vaccine developers have said that it may take up to a year before something is ready for distribution.

The ministers have come under pressure to explain the government's exit strategy from its continued closure, but scientists say it is too early to consider removing large-scale restrictions while the death toll remains on the rise.

Professor Robin Shattuck, from Imperial College London, made it clear at the end of March that vaccines would not be widely available until next year "as soon as possible," and he added in a statement to (BBC): "The first part of the test is to verify It is safe in humans in small numbers and again stimulates the right type of immune response. "

Period of time

Shattuck noted that this will take time even if we do things quickly, in a time period of two to three months, and continued: "The next stage will be to intensify it and start looking at whether the vaccine can actually prevent infection in society."

"You need to produce the data to show the vaccine worked and how successful it was before you could get a license to sell that as a product," said Professor Imperial College.

Third stage experiences

Usually, the third stage trials are needed most before clinically approval of the drug, "however, in emergency situations, these pilot vaccines are issued early to key workers," he noted.

Adrian Hill, director of the Jenner Institute at Oxford University, told the Guardian: "The more vaccines we can provide sooner, the better."

Professor Hill added: We are aware that a vaccine is required as soon as possible, and certainly by June and July when we expect a large peak in mortality.

He said: "This is not a normal case, we will follow all the requirements of the standard experimental safety, but once we have a vaccine that works, we expect that there will be a fast track to spread to save lives, the more we can provide a faster vaccine, the better."

The role of chimpanzees

The Jenner Institute team had announced that it had begun work to search for a vaccine on January 10 this year, and the institute said it had based the drug on an "adenovirus vaccine carrier" that is an adenovirus isolated from chimpanzees.

The Jenner Institute added: "Adenovirus chimpanzees are a well-studied vaccine type, which has been used safely in thousands of topics in vaccines targeting more than 10 different diseases," adding that among its advantages is that it can "generate a strong immune response from a single dose." Safe for use in people with previous conditions such as diabetes. "

Source / agencies

Comments